Urologists in Trials Boost
01 Jun 2017
Coverage in the Basingstoke Gazette of the HIFU trials taking place at North Hampshire hospital led by Richard Hindley. The story also includes comments from a HIFU patient of Richard Hindley and his delight at the procedure outcomes for his prostate cancer
Basingstoke Observer reports on HIFU treatment at NHH
23 May 2017
Recent coverage from the Basingstoke Observer on HIFU treatment available at NHH.
Richard Hindley and the team at North Hampshire Hospital are investing a lot of time and skills into offering the latest treatments in Urology for patients. The results coming in are promising and continue to prove that HIFU is a treatment worth investing in and offers patients further choice on treatment options for prostate cancer.
Greenlight proves to be cost effective as treatment for BPH
22 Mar 2017
Neil Barber was part of the team behind this study which proves GreenLight XPS provides equivalent clinical outcomes with fewer adverse events and shorter recovery time in a more cost-effective manner compared with TURP as treatment for BPH.
How the latest prostate cancer research might affect you
08 Mar 2017January 2017 saw the results of the PROMIS trial and the evidence confirmed that the use of a Multi Parametric MRI (mpMRI) scan provides a more accurate diagnosis for men before any biopsy has to be considered.
This is great news for patients as currently in many hospitals the gold standard is to go straight to Trans Rectal ultrasound guided biopsy (TRUS) which are very hit and miss. As a result, in these hospitals many men without cancer undergo unnecessary biopsies, and some men are over diagnosed with prostate cancer which is actually clinically unimportant. Furthermore the study showed that half of all clinically important cancers (those which need treatment to stop the cancer growing) are missed with the TRUS biopsy method.
In addition there are potential side effects, including pain, bleeding and infection.
The results of the trial show that one quarter of men may not need to undergo unnecessary prostate biopsy if they undergo an MRI. MRI also detects 93% of important cancers (compared with 48% for TRUS prostate biopsies).
It is important for patients to know that with the prostate gland, cancer can be detected but it doesn’t always mean radical treatment is necessary. Clinically insignificant cancer can be present but is unlikely to cause any problems during a man’s lifetime.
mpMRI for Prostate Cancer diagnosis in Hampshire
15 Feb 2017
Following the news of the PROMIS trials results and the positive data for mpMRI becoming part of the pathway for Prostate Cancer diagnosis, Hampshire Hospitals are able to offer this diagnostic to NHS patients. Richard Hindley was involved in the trial and patients from Hampshire were part of the study. Urology Partners have used mpMRI for diagnosis for a number of years and are delighted to see it move forward under the NHS.
PROMIS Results Full Report
20 Jan 2017Read the full report of the PROMIS trials which Richard Hindley.. was part of and bought in 160 patients from Hampshire and Surrey through North Hampshire Hospital
Genetic test tells patient if prostate cancer is likely to spread
10 Jan 2017
New research has discovered a genetic link to whether localised prostate cancer will advance and spread. If developed, this could allow far more personalised and specific treatment for patients with prostate cancer and knowing how they might respond to treatment.